Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival

Cancer

Volumn 119, Issue 1, 2013, Pages 26-35

  Sprenger, Thilo ^a   Conradi, Lena Christin ^a   Beissbarth, Tim ^a   Ermert, Heiko ^a   Homayounfar, Kia ^a   Middel, Peter ^a   Rüschoff, Josef ^b   Wolff, Hendrik A ^a   Schüler, Philipp ^a   Ghadimi, B Michael ^a   Rödel, Claus ^c   Becker, Heinz ^a   Rödel, Franz ^c   Liersch, Torsten ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Institute for Pathology Nordhessen   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

CD133; colorectal cancer stem cells; metastasis; preoperative radiochemotherapy; rectal cancer; survival

Indexed keywords

CD133 ANTIGEN; FLUOROURACIL; TUMOR MARKER;

ADULT; ADVANCED CANCER; ANTIGEN EXPRESSION; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PREOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RECTUM CARCINOMA; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR CELL; TUMOR REGRESSION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; GLYCOPROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; PEPTIDES; PROGNOSIS; RECTAL NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84872776909     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27703     Document Type: Article

References (31)

1. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351: 1731-1740.
2. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005; 23: 8688-8696.
3. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997; 90: 5002-5012.
4. O'Brien CA, Pollett A, Gallinger S, Dick JE,. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007; 445: 106-110.
5. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007; 445: 111-115.
6. Todaro M, Alea MP, Di Stefano AB, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007; 1: 389-402.
7. Burkert J, Wright NA, Alison MR,. Stem cells and cancer: an intimate relationship. J Pathol. 2006; 209: 287-297.
8. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T,. Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005; 5: 744-749.
9. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006; 66: 9339-9344.
10. Baumann M, Krause M, Hill R,. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer. 2008; 8: 545-554.
11. Ishii H, Iwatsuki M, Ieta K, et al. Cancer stem cells and chemoradiation resistance. Cancer Sci. 2008; 99: 1871-1877.
12. Ong CW, Kim LG, Kong HH, et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol. 2010; 23: 450-457.
13. Horst D, Scheel SK, Liebmann S, et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol. 2009; 219: 427-434.
14. Horst D, Kriegl L, Engel J, Kirchner T, Jung A,. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008; 99: 1285-1289.
15. Yasuda H, Tanaka K, Saigusa S, et al. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. Oncol Rep. 2009; 22: 709-717.
16. Kojima M, Ishii G, Atsumi N, Nishizawa Y, Saito N, Ochiai A,. CD133 expression in rectal cancer after preoperative chemoradiotherapy. Cancer Sci. 2010; 101: 906-912.
17. Saigusa S, Tanaka K, Toiyama Y, et al. Clinical significance of CD133 and hypoxia inducible factor-1alpha gene expression in rectal cancer after preoperative chemoradiotherapy. Clin Oncol (R Coll Radiol). 2011; 23: 323-332.
18. Saigusa S, Tanaka K, Toiyama Y, et al. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer. Oncol Rep. 2010; 24: 345-350.
19. Dallas NA, Xia L, Fan F, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009; 69: 1951-1957.
20. Iinuma H, Watanabe T, Mimori K, et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol. 2011; 29: 1547-1555.
21. Sobin LH,. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol. 2003; 21: 19-22.
22. Dworak O, Keilholz L, Hoffmann A,. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997; 12: 19-23.
23. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008; 118: 2111-2120.
24. Corbeil D, Roper K, Hellwig A, et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem. 2000; 275: 5512-5520.
25. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007; 1: 313-323.
26. Maeda S, Shinchi H, Kurahara H, et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer. 2008; 98: 1389-1397.
27. Horst D, Kriegl L, Engel J, Kirchner T, Jung A,. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 2009; 27: 844-850.
28. Saigusa S, Tanaka K, Toiyama Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 2009; 16: 3488-3498.
29. Kemper K, Sprick MR, de Bree M, et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 2010; 70: 719-729.
30. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444: 756-760.
31. Bujko K, Glynne-Jones R, Bujko M,. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol. 2010; 21: 1743-1750.